Answers are grounded in this paper and cite their sources.
The global antibiotic development pipeline is critically declining due to interconnected scientific, economic, regulatory, manufacturing, and policy challenges, worsening the antimicrobial resistance (AMR) crisis. The review examines the antibiotic pipeline from an industrial viewpoint, highlighting significant scientific, economic, and regulatory challenges. It proposes policy reforms and incentive models to encourage sustainable innovation and ensure equitable access to new antibiotics. Bacterial AMR was responsible for approximately 1.27 million deaths and associated with nearly 4.95 million deaths globally in 2019, notably in western sub-Saharan Africa. In the U.S., the CDC cites around 2.8 million resistant infections and over 35,000 deaths annually. Projections suggest that without action, AMR could lead to 10 million deaths per year by 2050 and result in multi-trillion USD economic losses. The review synthesizes findings from extensive literature across databases like PubMed and ScienceDirect, focusing on articles from January 2010 to June 2025, with an emphasis on high-quality evidence. The data underscore the urgent need for a comprehensive, multi-stakeholder strategy incorporating novel discovery platforms, push–pull economic incentives, adaptive regulatory pathways, and regionalized manufacturing models. Strengthening global partnerships between policymakers, funders, and industry is essential to rejuvenate the antibiotic pipeline, safeguard therapeutic effectiveness, and ensure equitable global access.
No takes yet. Share an insight, caveat, or question.
Moka et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: